Pediatric Gastroenterology, Hepatology & Nutrition

pghn

Original Article

Check for updates

Efficacy of Dairy Free Diet and 6-Food Elimination Diet as Initial Therapy for Pediatric Eosinophilic Esophagitis: A Retrospective Single-Center Study

Jonathan Wong,[1] Sue Goodine,[2] Kate Samela,[2] Katherine S. Vance,[2] Beth Chatfield,[2] Zhu Wang [ID],[1,3] and Wael N. Sayej [ID] [1,2]

[1]Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT, USA
[2]Department of Pediatrics, Division of Digestive Diseases, Hepatology and Nutrition, Connecticut Children's Medical Center, Hartford, CT, USA
[3]Department of Pediatric Research, Connecticut Children's Medical Center, Hartford, CT, USA

OPEN ACCESS

Correspondence to
Wael N. Sayej
Department of Pediatrics, Division of
Digestive Diseases, Hepatology and Nutrition,
Connecticut Children's Medical Center, 282
Washington Street, Hartford, CT 06106, USA.
E-mail: wsayej@connecticutchildrens.org

ORCID iDs
Zhu Wang [ID]
https://orcid.org/0000-0002-0773-0052
Wael N. Sayej [ID]
https://orcid.org/0000-0002-2519-517X

Conflicts of Interest
The authors have no financial conflicts of
interest.

ABSTRACT

Purpose: Management of eosinophilic esophagitis (EoE) varies from center to center. In this study, we evaluated the effectiveness of a dairy-free diet (DFD) and the 6-Food Elimination Diet (SFED) as initial therapies for the treatment of EoE in our practice.
Methods: This was a retrospective study of children who had been treated for EoE at Connecticut Children's Medical Center, Hartford, CT, USA. Pre- and post-treatment endoscopy findings and histology results of patients treated with DFD or SFED were examined.
Results: One hundred fifty-two patients (age 9.2±5.2 years, 76.3% male, 69.7% caucasian) met the inclusion criteria for initial treatment with DFD (n=102) or SFED (n=50). Response for DFD was 56.9% and for SFED was 52.0%. Response based on treatment duration (<10, 10–12, and >12 weeks) were 81.8%, 50.0%, and 55.1% for DFD, and 68.8%, 50.0%, and 40.0% for SFED. Response based on age (<6, 6–12, and >12 years) were 59.3%, 42.9%, and 67.5% for DFD, and 36.4%, 58.8%, and 72.7% for SFED. In patients treated with DFD, concomitant proton pump inhibitor (PPI) administration resulted in improved outcomes (p=0.0177). Bivariate regression analysis showed that PPI with diet is the only predictor of response (p=0.0491), however, there were no significant predictors on multiple regression analysis.
Conclusion: DFD and SFED are effective first line therapies for EoE. DFD should be tried first before extensive elimination diets. Concomitant therapy with PPI's may be helpful.

Keywords: Eosinophilic esophagitis; Restriction diet therapy; Proton pump inhibitors

INTRODUCTION

Eosinophilic esophagitis (EoE) is an emerging disease in the field of pediatric gastroenterology. While evidence of this condition has been present since the 1960s, characterization of the disease did not occur until 1993 [1]. Kelly et al. [2] were the first to show that an elemental diet was effective in treating esophageal eosinophilia that was unresponsive to anti-reflux therapy. At the most basic level, EoE is characterized by the abnormal presence of eosinophils in the squamous epithelium of the esophagus. The diagnosis of EoE requires a combination of both clinical and pathologic findings, including

Generated by xmlinkpress

the following: symptoms related to esophageal dysfunction, the presence of eosinophils on esophageal mucosal biopsy (≥15 eosinophils per high-power field), isolated eosinophilia in the esophagus, and the absence of any secondary causes [3]. Since the recognition of EoE in the 1990s, our understanding of this condition has improved but many questions remain unanswered, including the exact pathophysiology, characteristic histological findings, therapeutic endpoints, as well as biomarkers and molecular signatures that can aid in diagnosis [3,4].

Increased interest in more specific treatment guidelines has spurred research into the efficacy of current recommendations. Treatment options for this condition currently include medical therapies such as high-dose proton pump inhibitors (PPIs) [5-7], topical corticosteroids [8-12], and elimination diets such as elemental [13], empiric [14-17], and specific or directed elimination diets [15,16,18,19]. End points for treatment of EoE include improvements in both clinical symptoms as well as evidence of histologic response [3,16,18,20,21]. Treatment of EoE frequently requires a combination of both dietary and medical therapy. Two common dietary interventions include the dairy-free diet (DFD) [19] and the costly six-food elimination diet (SFED) [22]. The efficacies of these interventions were first demonstrated in 2006 and 2012, respectively, and they have shown continued success since their introduction [16,18,20,21]. Milk has been identified as the most common food trigger, followed by wheat [20]. Recent research has demonstrated the efficacy of additional diets such as the 4-food elimination diet, which has the advantage of covering major allergens while at the same time being less restrictive than SFED [16]. Given the multiple treatment strategies available, it has been difficult to validate a specific treatment protocol. Nowhere is this more apparent than in selecting a dietary elimination protocol for a patient, since in addition to nutrition, the clinician must consider patient lifestyle, adherence to therapy, and caregiver resources [3,22].

In this retrospective study, we aimed to evaluate treatment responses to DFD and SFED as initial therapies. We also sought to identify factors that may contribute to the success or failure of treatment, and specifically analyzed the following: treatment duration, age, sex, concurrent medical therapy, and objective findings on endoscopy and histology prior to and after therapy.

MATERIALS AND METHODS

We conducted a retrospective study of patients who had been treated for EoE (n=345). Retrospective and prospective data were entered into a Microsoft Access database by a single individual in the department of pediatric gastroenterology at Connecticut Children's Medical Center, Hartford, CT, USA. This database was approved by the institutional review board at Connecticut Children's Medical Center (IRB#: 15-046-CCMC). This database included demographic information, therapies (both dietary and medical), patient-reported compliance, endoscopy results, histology/biopsy results, and laboratory results. A single user abstracted the data elements listed below into an Excel spreadsheet. Potential confounders in this study included compliance and ancillary therapies such as medications. Patients were treated by various providers in our practice, and dietary therapies were determined based on both provider and patient preferences.

Patient demographics and clinical data

Patients included in the study were compared in terms of their demographic, endoscopic, and histological characteristics. Demographic characteristics included age, sex, and ethnicity/race. Clinical characteristics included concomitant medication usage (PPI's) and history of atopic disease (asthma, eczema, and seasonal allergies).

Gross endoscopic findings such as trachealization, furrowing, abscesses, exudates, specks, and erosions were noted both before and after elimination diets. We also examined pre- and post-treatment histologic characteristics, including peak eosinophils per high-power field (eos/hpf) on esophageal biopsy. Histologic examination was performed using 2–3 biopsies from both the proximal and distal esophagus.

Inclusion and exclusion criteria

The main study inclusion criterion was the diagnosis of EoE as per guidelines and consensus statements [3,4], mainly the presence of ≥15 eos/hpf on esophageal biopsy. Additional criteria included utilization of any of the aforementioned dietary therapies as first-line treatment, endoscopy interval ≥6 weeks, and no evidence of outright non-compliance (patients admitting to not following the diet). Exclusion criteria were age ≥21 years at the time of diagnosis, lack of follow-up, second biopsy obtained >6 months after initiation of therapy (usually because of non-adherence to therapy), or the presence of inflammatory bowel disease. None of the patients in this cohort had Eosinophilic gastritis or Helicobacter pylori infection.

Outcomes

The primary outcome was histological response, defined as a decrease in eos/hpf to <15 after dietary therapy. Patients noted to have ≥15 eos/hpf were defined as treatment failures. An advantage of this study is that a single pediatric pathologist at our institution reviewed the pathology sections. We chose to assess response histologically rather than based on symptoms because histological improvement is an objective finding in a retrospective study, whereas symptoms cannot be reliably assessed.

The secondary outcome was improvement of gross endoscopic appearance. Endoscopic improvement was based on the resolution of noted furrowing, trachealization, abscesses, exudates, specks, and erosions.

Outcomes were further analyzed by duration of therapy prior to repeat endoscopy and by age. Patients were categorized into 3 groups based on therapy duration: <10 weeks, 10–12 weeks, and >12 weeks. Similarly, patients were separated into 3 age groups: <6 years, 6–12 years, and >12 years.

Statistical analysis

Statistical analysis was performed using Prism Software version 6.0 (GraphPad Software Inc., La Jolla, CA, USA) and the R program (version 3.0.1; R Development Core Team, 2013; http://www.r-project.org) from the R foundation for statistical computing (http://www.R-project.org). Data were described using mean±standard error of the mean. We utilized the *t*-test for continuous variables to determine statistical significance when comparing 2 groups. We also used the χ^2 method or contingency tables for categorical variables. We performed bivariate logistic and multivariate logistic regressions to identify predictors of response. Results were considered statistically significant at *p*<0.05.

RESULTS

Demographic and clinical characteristics of study groups

A total of 345 patients with confirmed EoE were included in the database. Of these, 234 were treated with dietary elimination and 111 were treated mainly with topical steroids (n=78), directed elimination based on positive allergy tests (n=7), or other dietary elimination combinations such as milk/soy- or milk/soy/wheat-free diets (n=26). Of the 234 patients treated with DFD or SFED, 82 were excluded due to non-compliance or insufficient data. Examples of non-compliance included failure to adhere to diet, failure to obtain repeat biopsy, or failure to follow up. Thus, a total of 152 patients were included in this study (DFD=102 and SFED=50). Patient characteristics and demographics are presented in **Table 1**. Two notable findings were that older patients were more likely to be started on DFD vs. SFED (p=0.0070), and overall treatment duration prior to repeat endoscopy was significantly longer in the DFD group compared to the SFED group ($p \leq 0.0001$).

Histological findings

The average pre-treatment eosinophil count was 45.9±2.0 eos/hpf in the overall sample, 42.2±2.3 eos/hpf in the DFD group, and 52.4±4.2 eos/hpf in the SFED group (p=0.0069). The average post-treatment eosinophil counts were 21.3±1.9 eos/hpf in the overall sample, 20.6±2.3 in the DFD group, and 19.0±4.1 in the SFED group. Eosinophil counts decreased significantly after treatment in the overall sample, in the DFD group, and in the SFED group; $p \leq 0.0001$, $p \leq 0.0001$, and $p \leq 0.0001$, respectively (**Table 2**).

Table 1. Patient demographics and clinical characteristics

Variable	DFD (n=102)	SFED (n=50)	Total (n=152)	p-value
Mean age (yr)	9.9±0.5 (0.6–20.8)	7.6±0.7 (1.0–20.1)	9.2±5.2 (0.6–20.8)	0.0070
Sex, male	78 (76.5)	38 (76.0)	116 (76.3)	0.9489
Race, caucasian/white	70 (68.6)	36 (72.0)	106 (69.7)	0.4252
Presence of atopic disease				
Asthma	28 (27.5)	24 (48.0)	52 (34.2)	0.0121
Eczema	13 (12.7)	14 (28.0)	27 (17.8)	0.0024
Any atopy	31 (30.4)	28 (56.0)	59 (38.8)	0.0023
Treatment data				
Treatment duration (d)	100.4±2.8 (22–170)	80.3±2.9 (31–136)	93.0±2.8 (22–170)	<0.0001
Overall response	58 (56.9)	26 (52.0)	84 (55.3)	0.8846
PPI during treatment	90 (88.2)	41 (82.0)	131 (86.2)	0.2952
Compliance issues	12 (11.8)	3 (6.0)	15 (9.9)	0.4773

Values are presented as mean±standard error of the mean (range) or number (%).
DFD: dairy free diet, SFED: 6-food elimination diet, PPI: proton pump inhibitor.
p-values were computed using t-test for numerical variables and χ^2 for categorical variables.

Table 2. Endoscopic and histologic data

Variable	DFD (n=102)	SFED (n=50)	All patients (n=152)	p-value
Abnormal endoscopic findings				
Pre-treatment	71 (69.6)	39 (78.0)	110 (72.4)	0.2770
Post-treatment	54 (52.9)	28 (56.0)	82 (53.9)	0.7222
p-value	0.0363	0.0005	0.0009	
Histology data				
Pre-treatment eos/hpf	42.2±2.3 (15–100)	52.4±4.2 (20–100)	45.8±2.0 (15–100)	0.0069
Post-treatment eos/hpf	20.6±2.3 (0–100)	19.0±4.1 (0–100)	21.3±1.9 (0–100)	0.6226
p-value	<0.0001	<0.0001	<0.0001	
Response (<15 eos/hpf)	58 (56.9)	26 (52.0)	84 (55.3)	0.5711
Remission (<5 eos/hpf)	42 (41.2)	18 (36.0)	60 (39.5)	0.3937

Values are presented as number (%) or mean±standard error of the mean (range).
DFD: dairy free diet, SFED: 6-food elimination diet, eos/hpf: eosinophils per high-power field.
p-values were computed using t-test for numerical variables and χ^2 for categorical variables.

Endoscopic findings

In the overall patient sample, abnormal endoscopic findings were observed in 72.4% (110/152) of patients before treatment, and persisted in 53.9% (82/152) of patients after treatment. In the DFD and SFED groups, pre-treatment abnormalities were identified in 69.6% (71/102) and 78.0% (39/50) of patients, respectively, and post-treatment abnormalities were noted in 52.9% (54/102) and 56.0% (28/50) of patients, respectively. There were significant improvements in post-treatment endoscopic findings in the overall sample, in the DFD group, and in the SFED group; $p=0.0009$, $p=0.0363$, and $p=0.0005$, respectively (**Table 2**).

Response to treatment with regard to treatment duration and patient age

The response across all treatment groups was 55.3% (84/152). There was no significant difference in treatment response when DFD 56.9% (58/102) and SFED 52.0% (26/50) were used as primary therapies ($p=0.8846$). Among responders to DFD, SFED, or either, there were no significant differences when comparing patient groups defined by treatment duration (<10 weeks, 10–12 weeks, and >12 weeks) or by age (<6 years, 6–12 years, and >12 years) (**Table 3**).

In the DFD group (n=102), the therapy duration was <10 weeks in 11 patients, 10–12 weeks in 22 patients, and >12 weeks in 69 patients; the respective response rates in these 3 groups were 81.8% (9/11), 50.0% (11/22), and 55.1% (38/69). In the SFED group (n=50), the therapy duration was <10 weeks in 16 patients, 10-12 weeks in 14 patients, and >12 weeks in 20 patients; the respective response rates in these 3 groups were 68.8% (11/16), 50.0% (7/14), and 40.0% (8/20).

The response rate to DFD, based on age, was 59.3% (16/27) for age <6 years, 42.9% (15/35) for age 6–12 years, and 67.5% (27/40) for age >12 years. The response rate to SFED was 36.4% (8/22) for age <6 years, 58.8% (10/17) for age 6–12 years, and 72.7% (8/11) for age >12 years.

Treatment response in the presence or absence of atopy

Patients treated with SFED were significantly more likely to have asthma ($p=0.0121$), eczema ($p=0.0024$), or any atopy ($p=0.0023$) compared to patients treated with DFD (**Table 1**). The presence or absence of atopy was not significantly associated with treatment success, either in the overall patient sample or in patients categorized by response to DFD and SFED (**Table 4**).

Table 3. Response based on treatment duration and patient age

Variable	Response based on treatment duration (wk)				Response based on patient age (yr)			
	<10	10–12	>12	*p*-value	<6	6–12	>12	*p*-value
DFD responders	9/11 (81.8)	11/22 (50.0)	38/69 (55.1)	0.1915	16/27 (59.3)	15/35 (42.9)	27/40 (67.5)	0.0950
SFED responders	11/16 (68.8)	7/14 (50.0)	8/20 (40.0)	0.2260	8/22 (36.4)	10/17 (58.8)	8/11 (72.7)	0.1127
p-value	0.4464	1.0000	0.2350		0.1108	0.2797	0.7407	
All responders	20/27 (74.1)	18/36 (50.0)	46/89 (51.7)	0.0940	24/49 (49.0)	25/52 (48.1)	35/51 (68.6)	0.0623

Values are presented as number (%).
DFD: dairy free diet, SFED: 6-food elimination diet.
p-values were computed using χ^2 for categorical variables.

Table 4. Response based on other patient clinical characteristics and treatments

Variable	Evidence of atopy			Concomitant PPI therapy		
	No atopy	Atopy	*p*-value	No PPI	PPI	*p*-value
DFD responders	43/71 (60.6)	15/31 (48.4)	0.2534	3/12 (25.0)	55/90 (61.1)	0.0177
SFED responders	12/22 (54.5)	14/28 (50.0)	0.7495	5/9 (55.6)	21/41 (51.2)	0.8136
p-value	0.6159	0.9015		0.1536	0.2875	
All responders	55/93 (59.1)	29/59 (49.2)	0.2275	8/21 (38.1)	76/131 (58.0)	0.1014

Values are presented as number (%).
PPI: proton pump inhibitor, DFD: dairy free diet, SFED: 6-food elimination diet.
p-values were computed using χ^2 for categorical variables.

Table 5. Determinants of resolution/remission after treatment

Variable	Bivariable logistic regression				Multivariable logistic regression			
	Estimate	Standard error	Statistic	*p*-value	Estimate	Standard error	Statistic	*p*-value
Sex	−0.7967	0.4207	−1.894	0.0583	−0.6487	0.4391	−1.4770	0.1396
Age	0.0451	0.0370	1.219	0.2227	0.0401	0.0400	1.0030	0.3157
Primary Intervention SFED	−0.2389	0.4434	−0.539	0.5901	0.2004	0.5018	0.3990	0.6897
Any Atopy TRUE	−0.6848	0.4092	−1.674	0.0942	0.6825	0.4367	−1.5630	0.1181
PPI prior to diet intervention Yes	0.5833	0.3960	1.473	0.1410	0.4952	0.4207	1.1770	0.2392
PPI with diet Yes	1.5170	0.7708	1.968	0.0491*	1.3245	0.7923	1.6720	0.0946

Bivariate and multivariate regression model demonstrating determinants of response to treatment with outcome of resolution/remission.
*p-value <0.05 (statistically significant).

Treatment response with or without concomitant PPI therapy

Of the 152 patients on DFD or SFED, 131 (86.2%) underwent concurrent PPI therapy (**Table 1**). Treatment success was not significantly associated with PPI therapy in the overall patient sample (**Table 4**). However, patients treated with both DFD and concurrent PPI therapy (88%) had a significantly higher rate of treatment success than those on DFD alone (*p*=0.0177). This was confirmed with bivariate logistic regression analysis (*p*=0.0491) but not in the multivariate logistic regression (**Table 5**). This difference was not observed in patients who received SFED with or without PPI therapy. None of our patients were treated with what is considered high dose PPI therapy while on dietary therapy.

DISCUSSION

In this retrospective study, we sought to evaluate the efficacy of DFD and SFED as first-line therapies for the treatment of EoE in our practice. This was not intended to be a head-to-head comparison but rather a comparison of first line options. Treatment with DFD and SFED as first-line therapies resulted in responses in 57% and 52% of children, respectively. These response rates were not surprising given the results of previous studies. In a retrospective study, Kagalwalla et al. [19] showed that the response to DFD was 65% when used as the initial therapy for EoE treatment. In a second retrospective study, this same group found that 75% of patients responded to SFED [18]. In a meta-regression analysis, Cotton et al. [23] showed an overall response rate of 69% to SFED (95% prediction limits 31.9–91.4%).

While multiple therapies have been shown to be effective for EoE, optimal treatment protocols remain elusive due to the need to tailor treatment to individual patients. We anticipated that patients with longer intervals between endoscopies would have increased response rates due to decreased antigen loads. However, as noted above, there was no significant difference between treatment groups with regards to treatment duration; patients treated <10 weeks had the highest response rate, but this finding was not statistically significant. Given this finding, decisions on the duration of therapy prior to repeat endoscopy should be based on a combination of factors, including patient adherence and the complexity of dietary therapy. We suspect that the longer the endoscopy interval, the more likely it is that the patient will become non-adherent, as seen in those who underwent repeat endoscopy after very long intervals (>6 months) and were eventually excluded. Most studies on dietary management of EoE performed endoscopies at intervals of 6–8 weeks. The consensus statements from 2007 and 2011 recommended treatment of 6–12 weeks (depending on the treatment) between endoscopies [3,24]. The 2018 AGREE conference was not clear nor specific with regards to the duration between endoscopies [3]. Our practice

is to do endoscopies at intervals of 8–12 weeks to minimize the number of endoscopies and anesthesia done in a short period of time.

Additionally, and surprisingly, response rates in the treatment groups did not differ with respect to age. We hypothesized that since parents would be more likely to manage younger patients' diets, these patients might have better compliance and thus, higher response rates. In fact, there was no significant difference between age groups, but surprisingly, older patients had numerically higher response rates. Additionally, older patients were more likely to be started on DFD rather than SFED (p=0.0070). This is generally done to minimize the difficulties that teenagers may face with dietary restrictions and to improve compliance.

The majority of patients (85%) underwent concomitant PPI therapy with the dietary elimination. Patients treated with both DFD and PPI therapy fared better than those who did not receive PPI therapy (p=0.0177). This was confirmed with bivariate logistic regression analysis (**Table 5**). There was no difference in the SFED group with respect to concomitant PPI therapy. PPIs have been shown to significantly inhibit IL-4–stimulated eotaxin-3 expression in EoE esophageal cells and to block STAT6 binding to the eotaxin-3 promoter [25]. Additionally, PPIs might have eosinophil-reducing effects independent of their influence on acid reflux, and response to PPIs might not distinguish EoE from gastroesophageal reflux disease [26]. Therefore, it is not surprising that patients who underwent an elimination diet with concomitant PPI therapy responded more favorably.

Since an association between atopic diseases and EoE has previously been demonstrated [27-29], we compared treatment outcomes between those with and without evidence of atopic disease. There was no significant association, either in the overall sample or in treatment subgroups (**Table 4**). While atopy is helpful in the diagnosis of EoE, it does not appear to be applicable as a predictor of treatment response.

Significant improvement of gross endoscopic appearance was noted in the overall sample as well as in treatment subgroups (**Table 2**). It would have been optimal to compare these results with associated symptomatology, but the database did not include sufficient data on symptoms.

This study has several strengths. It reflects the comprehensive nature of real-life practice at a single major children's healthcare facility. The sample size is one of the largest in any pediatric or adult studies. While treatment approaches vary from practice to practice, we report on a single department experience where clinical decisions were similar among the providers. Retrospective and prospective data input was performed by a single individual, which decreased variability in reported patient profiles. Furthermore, an advantage of the database is that the same information was available for all patients.

A major exclusion criterion for this study was compliance with dietary therapy; while the database provided evidence on many occasions, these were restricted to subjective observations and patient admittance. As in any study, compliance is difficult to measure. In multiple instances, issues with compliance did not become apparent until the follow-up endoscopy, which voided the usefulness of the follow-up biopsy.

One of the weaknesses of this study was the lack of uniformity in treatment courses between patients. Despite having limited therapeutic options for EoE, general pediatric and adult practices across the country vary in their treatment approaches. On secondary analysis of

our data it was noted that a significant number of patients (52%) started on DFD and a PPI had no prior PPI exposure. This makes it difficult to interpret response rates as this subset of patients were exposed to two recognized forms of treatment for EoE simultaneously. However, we would like to highlight the fact that none of our patients received what is considered to be high dose PPI therapy before or during treatment with dietary therapy. Standardized dosing was also difficult to identify as patients were noted to be on multiple formulations of PPI (i.e. omeprazole, lansoprazole) which have variable dosing based on age and weight. Lastly, our database did not include actual dosing of PPI therapy. Given this, PPI administration in these cases should be viewed as an adjunctive therapy vs dual therapy.

A major area of future research is the development of stepwise treatment protocols. Developing and validating a step-up treatment approach to EoE, in contrast to the commonly used top-down methods, would be a valuable tool for practitioners. We believe that starting with a dairy free diet as first line therapy, with or without PPI, is warranted. This should be followed by a 4- or 6-food elimination diet or oral topical steroids. Optimization of such a protocol could lead to decreased time to remission along with potential decreases in endoscopic procedures. These diets should be tried in addition to directed elimination diets based on allergy testing in patients with multiple food allergies. In these patients, it is not unreasonable to proceed with SFED or even more restrictive diets such as a hypoallergenic diet or an elemental diet if necessary. Further prospective studies are warranted to identify the most effective treatment approach.

CONCLUSION

DFD is an effective initial therapy for EoE and should be attempted before more extensive and costly elimination diets [22]. This has the advantage of eliminating one of the most common offending agents in EoE while remaining minimally restrictive. High-dose PPI therapy remains an important treatment option for EoE, however, adverse effects with long term use of PPI's has raised concerns. Concomitant use of PPIs with dietary therapy is also advised until a repeat endoscopy is performed. We believe that this warrants further studies and a prospective trial to evaluate a step-up approach to treating EoE in children and adults.

REFERENCES

1. Attwood SE, Smyrk TC, Demeester TR, Jones JB. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci 1993;38:109-16.
   PUBMED | CROSSREF
2. Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology 1995;109:1503-12.
   PUBMED | CROSSREF
3. Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128:3-20.e6; quiz 21-2.
   PUBMED | CROSSREF
4. Furuta GT. Eosinophilic esophagitis: update on clinicopathological manifestations and pathophysiology. Curr Opin Gastroenterol 2011;27:383-8.
   PUBMED | CROSSREF

5. Sayej WN, Patel R, Baker RD, Tron E, Baker SS. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2009;49:393-9.
    PUBMED | CROSSREF

6. Dranove JE, Horn DS, Davis MA, Kernek KM, Gupta SK. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr 2009;154:96-100.
    PUBMED | CROSSREF

7. Molina-Infante J, Hernandez-Alonso M, Vinagre-Rodriguez G, Martin-Noguerol E. Proton pump inhibitors therapy for esophageal eosinophilia: simply following consensus guidelines. J Gastroenterol 2011;46:712-3; author reply 714-5.
    PUBMED | CROSSREF

8. Aceves SS, Dohil R, Newbury RO, Bastian JF. Topical viscous budesonide suspension for treatment of eosinophilic esophagitis. J Allergy Clin Immunol 2005;116:705-6.
    PUBMED | CROSSREF

9. Dohil R, Newbury R, Fox L, Bastian J, Aceves S. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010;139:418-29.
    PUBMED | CROSSREF

10. Fable JM, Fernandez M, Goodine S, Lerer T, Sayej WN. Retrospective comparison of fluticasone propionate and oral viscous budesonide in children with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2018;66:26-32.
    PUBMED | CROSSREF

11. Teitelbaum JE, Fox VL, Twarog FJ, Nurko S, Antonioli D, Gleich G, et al. Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. Gastroenterology 2002;122:1216-25.
    PUBMED | CROSSREF

12. Konikoff MR, Noel RJ, Blanchard C, Kirby C, Jameson SC, Buckmeier BK, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006;131:1381-91.
    PUBMED | CROSSREF

13. Markowitz JE, Spergel JM, Ruchelli E, Liacouras CA. Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol 2003;98:777-82.
    PUBMED | CROSSREF

14. Spergel JM, Andrews T, Brown-Whitehorn TF, Beausoleil JL, Liacouras CA. Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Ann Allergy Asthma Immunol 2005;95:336-43.
    PUBMED | CROSSREF

15. Molina-Infante J, Arias Á, Alcedo J, Garcia-Romero R, Casabona-Frances S, Prieto-Garcia A, et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: the 2-4-6 study. J Allergy Clin Immunol 2018;141:1365-72.
    PUBMED | CROSSREF

16. Kagalwalla AF, Wechsler JB, Amsden K, Schwartz S, Makhija M, Olive A, et al. Efficacy of a 4-food elimination diet for children with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2017;15:1698-707.e7.
    PUBMED | CROSSREF

17. Wechsler JB, Schwartz S, Amsden K, Kagalwalla AF. Elimination diets in the management of eosinophilic esophagitis. J Asthma Allergy 2014;7:85-94.
    PUBMED | CROSSREF

18. Kagalwalla AF, Sentongo TA, Ritz S, Hess T, Nelson SP, Emerick KM, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006;4:1097-102.
    PUBMED | CROSSREF

19. Kagalwalla AF, Amsden K, Shah A, Ritz S, Manuel-Rubio M, Dunne K, et al. Cow's milk elimination: a novel dietary approach to treat eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2012;55:711-6.
    PUBMED | CROSSREF

20. Kagalwalla AF, Shah A, Li BU, Sentongo TA, Ritz S, Manuel-Rubio M, et al. Identification of specific foods responsible for inflammation in children with eosinophilic esophagitis successfully treated with empiric elimination diet. J Pediatr Gastroenterol Nutr 2011;53:145-9.
    PUBMED | CROSSREF

21. Kagalwalla AF, Shah A, Ritz S, Melin-Aldana H, Li BU. Cow's milk protein-induced eosinophilic esophagitis in a child with gluten-sensitive enteropathy. J Pediatr Gastroenterol Nutr 2007;44:386-8.
    PUBMED | CROSSREF

22. Asher Wolf W, Huang KZ, Durban R, Iqbal ZJ, Robey BS, Khalid FJ, et al. The six-food elimination diet for eosinophilic esophagitis increases grocery shopping cost and complexity. Dysphagia 2016;31:765-70.
   PUBMED | **CROSSREF**

23. Cotton CC, Eluri S, Wolf WA, Dellon ES. Six-food elimination diet and topical steroids are effective for eosinophilic esophagitis: a meta-regression. Dig Dis Sci 2017;62:2408-20.
   PUBMED | **CROSSREF**

24. Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, et al.; First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133:1342-63.
   PUBMED | **CROSSREF**

25. Zhang X, Cheng E, Huo X, Yu C, Zhang Q, Pham TH, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One 2012;7:e50037.
   PUBMED | **CROSSREF**

26. Cheng E, Zhang X, Huo X, Yu C, Zhang Q, Wang DH, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut 2013;62:824-32.
   PUBMED | **CROSSREF**

27. Benninger MS, Strohl M, Holy CE, Hanick AL, Bryson PC. Prevalence of atopic disease in patients with eosinophilic esophagitis. Int Forum Allergy Rhinol 2017;7:757-62.
   PUBMED | **CROSSREF**

28. Aceves SS. Food allergy testing in eosinophilic esophagitis: what the gastroenterologist needs to know. Clin Gastroenterol Hepatol 2014;12:1216-23.
   PUBMED | **CROSSREF**

29. Aceves SS. Food and aeroallergens in eosinophilic esophagitis: role of the allergist in patient management. Curr Opin Gastroenterol 2014;30:391-5.
   PUBMED | **CROSSREF**